About us

Ola Holmlund - CEO

CEO since 2018. Former Head of Sales at Kibion AB, Ola Holmlund has served in senior sales and business development roles in a wide range of technology and life science companies for more than 20 years, including Biolin Scientific AB, COSMED srl, and Aerocrine AB. He has a BSc in Business Administration from International University of Monaco, and is a Certified Coach with the COPA International Coaching Community.
Other assignments: –
Born: 1969
Holdings in Lipidor AB: 370,000 shares, 45,000 options.

Charlotta Ekman - CFO

Chief Financial Officer since 2022. Trained economist and holds a master’s degree in business development. Charlotta has previous experience from a number of leading positions as CFO and COO at innovative and expansive companies. Before her employment at Lipidor, she worked at Minesto AB (publ) and Acosense AB (publ), among others.
Ongoing assignments: Board member of  Addace Consulting AB.
Previous assignments in the past five years: CFO of Acosense AB.
Born: 1981
Holdings in the Company: 25, 000 options.

Jan Holmbäck - CSO

Co-founder and in the Chief Scientific Officer position since 2010. PhD, Dr Holmbäck has more than 30 years of experience from the pharmaceutical industry in the fields of analytical and organic chemistry. He is specialized in the characterization of lipid materials, particularly by spectroscopic and chromatographic methods, and the use of lipids in drug delivery systems. Previous appointments include positions at Kabi, Pharmacia, and as Senior Scientist at LipoCore. Dr Holmbäck holds a PhD in Organic Chemistry from the Royal Institute of Technology, Stockholm.
Other assignments: CEO and Board member of SumIT System Aktiebolag.
Born: 1957
Holdings in Lipidor AB: 818,811 shares, 45,000 options.

Anders Hagman - CDO

In the Chief Development Officer position since 2020. Anders Hagman holds a PhD and Master’s degree in Analytical Chemistry from Stockholm University. He has over 30 years of experience from leading positions and expert roles in the life science sector. For the past 10 years, he has worked as CDO and QC manager for Cobra Biologics. Also, experience from the role as CMC consultant at AP Hagman Consulting AB with clients such as Alfa Laval AB, Clinstorage AB and Q&Q Labs AB.
Other assignments: –
Born: 1958
Holdings in Lipidor AB: 18,000 shares, 45,000 options.

Fredrik Sjövall

Chairman since 2020, Board member since 2018. CEO of Inhalation Sciences AB. Graduated from the Chalmers University of Technology (MSc). Previous appointments include CEO at PharmaSurgics and Lipopeptide (currently Promore Pharma). Sjövall has spent more than 10 years as the CEO of early stage companies in the life science industry.
Other assignments: Chairman of Ziccum AB and Board member of Axelero Aktiebolag.
Previous assignments: Chairman of Hemcheck Sweden AB.
Born: 1980
Holdings in Lipidor AB:  50,000 shares (privately and through company).

Independent in relation to Lipidor, its management and major shareholders.

Ola Flink

Board member since 2017. Pharmacist. Brings experience from more than 30 years in the pharmaceutical drug development industry.
Other assignments: Chairman of Pens. Farmaceuters Förbund and Board member of Ola Flink Consulting AB.
Previous assignments: Board member of Umecrine Cognition AB, Marbileads AS in Norway and Asarina Pharma AB (publ).
Born: 1944
Holdings in Lipidor AB: 482,000 shares (privately and through company).

Independent in relation to Lipidor, its management and major shareholders.

Gunilla Lundmark

Board member since 2020. CEO of Uppsala University Holding Company AB. BSc and Executive MBA. Previous appointments include CEO for Pharmanest AB and vice president for Q-Med AB. Gunilla has 30 years of experience in the life science industry.
Other assignments: CEO of Uppsala universitet Invest AB and Board member of Chordate Medical Holding AB (publ), Chordate Medical AB, Uppsala Innovation Centre AB, Institutet för Personal- och Företagsutveckling AB, Uppsala universitets Projekt AB, Uppsala universitet Research Intellectual Property AB and Uppsala-Gruppen Utbildning & Organisation AB.
Born: 1963
Holdings in Lipidor AB: –

Independent in relation to Lipidor, its management and major shareholders.

Otto Skolling

Board member since 2020. Master’s degree in Chemical Engineering from the Royal Institute of Technology in Stockholm. Otto has 20 years of broad experience in the pharmaceutical and medical technology industries, including product development, business development and project management that he earned through leading positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn.
Other assignments: Responsible for Business Development at Nanexa, Chief Business Officer at Asarina Pharma AB, Board member of Nanexa, Athera Biotechnologies AB and Bactaviva AB. CEO and Board member of Isles of Wines AB as well as Chairman and CEO of Pharmor AB.
Born: 1961
Holdings in Lipidor AB: –

Independent in relation to Lipidor, its management and major shareholders.

Denis Angioletti

Board member since 2020. University degree in pharmaceutical chemistry and engineering from Milan University. Denis has more than 20 years of experience in the pharmaceutical and bulk API industry in Europe.
Other assignments: CCO of Cerbios Pharma AS.
Previous assignments: Deputy CEO for the pharma division of Summit Pharmaceutical Europe, 2013-2017.
Born: 1968
Holdings in Lipidor AB: –

Independent in relation to Lipidor, its management and dependent in relation to the major shareholders.

Bengt Herslöf

PhD, Prof, Senior Scientific Advisor Dr Herslöf has over 40 years of experience working with lipid sciences in the areas of pharmaceuticals and food, including positions at Karlshamns AB and KabiVitrum AB. In 1986 he co-founded and was the CEO of LipidTeknik AB, which became LTP Lipid Technologies Provider AB in 2001, and was acquired by DSM in 2006. Dr Herslöf received his PhD in Organic Chemistry at Lund University, Sweden. Co-founder.

Anders Carlsson

PhD, Senior Advisor. Dr Carlsson has more than 30 years of industrial experience in pharmaceutical development, specializing within the fields of applied colloid and surface science, liquid and semi-solid pharmaceutical formulations, and drug delivery systems. He has vast experience of business development in the field. He is also active in his consultancy company MediGelium AB. AKVANO is based on an original idea by MediGelium. He has a PhD in Physical Chemistry from Lund University, Sweden. Co-founder.

Jan Holmbäck

PhD, Chief Scientific Officer Dr Holmbäck has more than 30 years of experience from the pharmaceutical industry in the fields of analytical and organic chemistry. He is specialized in the characterization of lipid materials, particularly by spectroscopic and chromatographic methods, and the use of lipids in drug delivery systems. Previous appointments include positions at Kabi, Pharmacia, and as Senior Scientist at LipoCore. Dr Holmbäck holds a PhD in Organic Chemistry from the Royal Institute of Technology, Stockholm. Co-founder.

Gerhard Miksche

PhD; Associate Prof. (Gothenburg University), Dr Miksche has extensive experience in pharmaceutical development and Intellectual Property Right management. Previous appointment include lecturer in Organic Chemistry, Lund University, Head of Chemical Dept., Workers Protection Agency 1976-77; Dept. Director (Pharmaceuticals and Medical Technology) at Swedish Governmental Board of Technological Development (STU) and Head of AB Astra Patent & TM Dept. Dr Miksche is currently active as Intellectual Property Consultant (Conimar AB & Inproc AB).
Co-founder.

Olle Holmertz

Business Controller Mr Holmertz has 15 years of experience from positions as CEO, CFO, Investor and Board member in technology companies (medical and other) and venture capital firms. Previous appointments include CFO of LTP Lipid Technologies Provider AB, and CIMON Medical AB. Mr Holmertz has an MSc in Business Administration and Economics from Lund University, Sweden. Co-founder.